The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Ocrevus is a medicine commonly used to treat primary progressive MS, but it can take up to four hours to receive intravenously. A new version called “Ocrevus Zunovo” was recently approved by ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

During the first half of this year, Ocrevus generated 1.04 billion Swiss francs – more than 90% of that was from use in the US. Roche’s MS drug Ocrevus earns blockbuster status a year after ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Ocrevus sales increased 11% to 1.69 billion Swiss francs, while Vabysmo surged 59%. On Wednesday, Roche Holdings AG RHHBY released its third-quarter sales report. Sales increased 9% year over year ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

This damages the nerves and may lead to a variety of symptoms, including numbness, vision problems, muscle weakness, and ...

Moreover, high-efficacy monoclonal antibody therapy -- ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri) - ...